Offering a population of 65-year-old men with SAAs (re)screening after 5 years would generate a significantly higher yield, with an estimated proportion of nearly 30 per cent developing clinically relevant AAAs after 10 years. The gene discussed is PCSK1N; the disease is achalasia-alacrima syndrome.